



# CIGNA MEDICAL COVERAGE POLICY

The following Coverage Policy applies to all health benefit plans administered by CIGNA Companies including plans formerly administered by Great-West Healthcare, which is now a part of CIGNA.

**Subject Excimer Laser Coronary Angioplasty (ELCA)**

**Effective Date ..... 5/15/2010**  
**Next Review Date ..... 5/15/2012**  
**Coverage Policy Number ..... 0342**

## Table of Contents

Coverage Policy .....	1
General Background .....	1
Coding/Billing Information .....	4
References .....	5
Policy History .....	7

## Hyperlink to Related Coverage Policies

Brachytherapy of the Coronary Arteries  
Drug-Eluting Stents for Ischemic Heart Disease

### INSTRUCTIONS FOR USE

Coverage Policies are intended to provide guidance in interpreting certain **standard** CIGNA HealthCare benefit plans. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement (GSA), Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document **always supercedes** the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. Proprietary information of CIGNA. Copyright ©2011 CIGNA

## Coverage Policy

**CIGNA does not cover excimer laser coronary angioplasty (ELCA), because it is considered experimental, investigational or unproven.**

## General Background

Excimer laser coronary angioplasty (ELCA) was introduced in the 1980s as an alternative method of angioplasty intended to reduce the long- term complications and high restenosis rates associated with other angioplasty and stenting techniques. This procedure was introduced prior to the introduction and widespread use of drug-eluting stents, which have greatly reduced the incidence of restenosis and in-stent restenosis. ELCA removes atherosclerotic plaque by laser ablation. The excimer laser generates high-power ultraviolet pulses through a fiberoptic catheter. The pulses vaporize thin sections of tissue without causing significant damage to surrounding tissue. It was hypothesized that reduction of atherosclerotic tissue mass using laser ablation with or without balloon dilation could be more effective in enlarging the vessel lumen than balloon angioplasty alone. Early data from large observational registry studies published in the early 1990s provided evidence of the safety of ELCA for patients with coronary lesions suitable for treatment by conventional PTCA.

### U.S. Food and Drug Administration (FDA)

The Spectranetics CVX-300® Excimer Laser Coronary Angioplasty (ELCA) system (Spectranetics Corporation, Colorado Springs, CO) was granted marketing approval by the FDA on March 24, 1993. The premarket approval states that the device is indicated for use in patients with single or multivessel coronary artery disease,

as a stand-alone modality or in conjunction with PTCA. It was approved for patients who are acceptable candidates for CABG and have occluded saphenous vein bypass grafts, ostial lesions, long lesions (greater than 20 mm in length), moderately calcified stenoses, total occlusions traversable by a guide wire and lesions that have previously failed balloon angioplasty. On October 10, 2001, treatment of restenosis in stainless steel stents prior to the administration of intravascular brachytherapy was added by the FDA as an approved indication for ELCA.

### **Literature Review**

**Coronary Artery Stenosis:** Two randomized trials of ELCA were initiated in the 1990s based on early promising data. Appelman et al. (1996) conducted a randomized, controlled trial to compare ELCA with traditional balloon angioplasty. Patients with stable angina and coronary lesions larger than 10 mm on visual assessment were included. A total of 308 patients were randomized, with 151 patients (158 lesions) randomly assigned to ELCA and 157 patients (167 lesions) to balloon angioplasty. Because the majority of patients received balloon angioplasty following ELCA in order to achieve optimal vessel dilation, a true determination of ELCA alone compared to balloon angioplasty was not possible. The researchers reported that ELCA followed by balloon angioplasty provides no additional benefit than balloon angioplasty alone with respect to the initial and long-term clinical angiographic outcome in the treatment of obstructive coronary artery disease. A subsequent analysis of the same population (Appelman, et al., 2000) compared functional outcomes of ELCA and balloon angioplasty. The researchers reported that ELCA and balloon angioplasty yield similar long-term functional outcomes, as measured by anginal status, exercise tolerance and myocardial perfusion.

Reifart et al. (1997) published a randomized controlled trial to determine whether revascularization with ELCA or rotational atherectomy can improve initial angiographic and clinical outcomes compared to balloon angioplasty alone. A total of 685 patients with symptomatic coronary disease who required revascularization for complex lesions were randomly assigned to balloon angioplasty (n=222), ELCA (n=232) or rotational atherectomy (n=231). The primary endpoint was procedural success, defined as stenosis diameter less than 50% and absence of death, Q-wave myocardial infarction or CABG. Overall, 93% of the ELCA group received adjunctive balloon dilatation to achieve the final angiographic result. Patients who underwent rotational atherectomy had higher rates of procedural success (89%) than those who underwent ELCA (77%) or balloon angioplasty (80%), but at six-month follow-up, revascularization of the original lesion was required more frequently in the atherectomy group (42%) and the ELCA group (46%) than in the balloon angioplasty group (32%). The authors reported that the role of plaque debulking prior to balloon dilatation in percutaneous revascularization remains to be fully defined.

**In-Stent Restenosis:** ELCA has also been evaluated as a treatment for in-stent restenosis (ISR). In a small case series (n=98) conducted by Mehran et al. (1997), the clinical safety, mechanisms and six-month results of ELCA with adjunctive PTCA were compared to those of PTCA alone for the treatment of in-stent restenosis. This study was relatively small with a brief follow-up period. The researchers reported that ELCA+PTCA appeared to be superior to PTCA alone for in-stent restenosis but that a prospective, randomized trial comparing PTCA alone versus ELCA plus PTCA or other ablative techniques was warranted.

Köster et al. (1999) conducted a multi-center prospective study (n=440) to evaluate ELCA with adjunctive balloon angioplasty in the treatment of ISR. Device success was defined as less than 50% stenosis after ELCA, while procedure success was defined as ELCA success followed by less than 30% stenosis, with or without angioplasty. ELCA was combined with balloon angioplasty in 99% of patients. The device success rate was 92%, and the procedure success rate was 91%. The researchers reported that ELCA with balloon angioplasty is a safe and efficient technology to treat ISR. This was a nonrandomized uncontrolled study, however, with no comparison to balloon angioplasty alone and no follow-up beyond the initial period of hospitalization.

A subsequent study of 96 consecutive patients successfully treated with ELCA within 141 stents analyzed six-month clinical and angiographic data (Köster, et al., 2000). Mean diameter stenosis was  $77 \pm 12\%$  prior to intervention and decreased to  $41 \pm 12\%$  after ELCA and  $11 \pm 12\%$  following adjunctive PTCA. Six months after ELCA, however, the mean diameter stenosis had increased to  $60 \pm 26\%$ . Stenosis greater than 50% was present in 48 (54%) patients. The authors suggested that ELCA is unlikely to reduce recurrent ISR and that other approaches are necessary.

Mehran et al. (2000) conducted a retrospective clinical trial (n=249) to compare the mechanisms and clinical results of ELCA versus those of rotational atherectomy (RA), each followed by adjunct PTCA. ELCA+PTCA was

performed on 119 patients (158 ISR lesions), and RA+PTCA was performed on 130 patients (161ISR lesions). There was no significant difference between the two groups in post-procedure luminal-dimension measurements, angiographic success or in-hospital complication rates. Target lesion revascularization rates at one year were comparable: 26% with ELCA+PTCA and 28% with RA+PTCA. The author stated that if atheroablation was a strong determinant of clinical outcome, then differences between atheroablative devices with respect to ablation efficiency and the amount of intimal hyperplasia removed should translate into improved long-term clinical benefit. ELCA+PTCA and RA+PTCA improved lumen dimension by tissue ablation, tissue extrusion and additional stent expansion. Although RA achieved greater intimal hyperplasia ablation, it did not result in improved one-year outcomes. The author reported that either combination of procedures could be used to treat ISR with similar clinical results.

Batyrallyev et al. (2006) conducted a non-randomized experimental study (n=125) to evaluate angiographic and clinical outcomes of PTCA alone and in combination with ELCA in patients with in-stent restenosis. ELCA was performed prior to balloon dilation in 67 patients, and PTCA alone was performed in 58 patients. Immediate angiographic results were comparable in both groups, with success rates of 98.3% in the PTCA group and 98.5% in the ELCA + PTCA group. Follow-up at one year showed similar major adverse cardiac events (MACE) and target vessel revascularization rates.

**Acute Coronary Syndrome and Acute Myocardial Infarction:** ELCA has more recently been proposed as a treatment for patients with an evolving acute myocardial infarction (AMI) with thrombus-laden lesions. Current standard therapy involves either thrombolytic therapy or balloon angioplasty. Thrombolytic agents are limited by anterograde coronary flow, which is restored in only 50-60% of patients, and reocclusion of the infarcted artery occurs in 20-30% of treated vessels in patients who receive this therapy. Patients who experience ongoing chest pain after thrombolytic therapy or those with contraindications to thrombolytics often need PCI for removal of an occlusive thrombus and underlying atherosclerotic plaque. Treatment with ELCA has been explored as a possible alternative, since both atherosclerotic plaque and thrombi readily absorb laser energy.

In the CARMEL (Cohort of Acute Revascularization in Myocardial Infarction with Excimer Laser) multi-center trial, 151 patients with AMI underwent ELCA between 1997 and 2002 at eight participating medical centers (Topaz, et al., 2004). Eligibility for this non-randomized observational study included evolving MI within 24 hours of symptom onset necessitating urgent PCI for continuous chest pain and/or ischemia. The study included patients who failed to respond to thrombolytic agents or had contraindications to thrombolytics. Patients with cardiogenic shock and agents for whom an old saphenous vein graft was the infarct-related vessel were also included. Patients were selected for enrollment if angiographic characteristics known to increase the risk of balloon angioplasty (e.g., thrombus and complex morphology of the underlying plaque) were present in the target lesion. The primary endpoints of the study were device, angiographic success and procedural success, with secondary endpoints of documentation of major adverse cardiac events (MACE), emergent CABG, or target revascularization during the treatment and hospitalization period. The minimal lumen diameter increased from  $0.5 \pm 0.5$  mm to  $1.6 \pm 0.5$  mm after laser treatment and increased to  $2.7 \pm 0.6$  mm after adjunctive balloon angioplasty and stenting, and the mean stenosis was reduced from  $83 \pm 17\%$  to  $52 \pm 15\%$  after ELCA and was reduced to  $20 \pm 16\%$  after adjunctive stenting. Of the six patients who died (4%), all had presented in cardiogenic shock. The authors reported that ELCA is an effective and safe modality for treatment of AMI and that maximal thrombus dissolution in lesions with extensive thrombus burden, significant increase in minimal luminal diameter and adequate restoration of anterograde TIMI (thrombolysis in myocardial infarction) flow to the infarct-related artery support successful debulking facilitated by ELCA. They also reported that, although the presence of cardiogenic shock does not affect the success of the technology, it remains a predictor of MACE during hospitalization. Although this study demonstrated that ELCA+PTCA is a promising technique that may be beneficial for patients with AMI who are not candidates for thrombolytic therapy, the study did not compare ELCA+PTCA with PTCA alone in a comparable patient population.

In a similar case series, Topaz et al. (2003) reported success in ELCA followed by adjunct balloon angioplasty and stenting for patients with depressed left ventricular function (LVF). Depressed left ventricular ejection fraction (LVEF) is often seen in patients with multivessel CAD and a history of MI. Symptomatic patients with depressed LVEF are a potentially high-risk group for PCI, since the major complication rate is higher in this group. The study included 100 patients with acute coronary syndromes: 51 with unstable angina and 49 with AMI. There were 25 patients (group 1) with decreased LVEF and 75 (group 2) with preserved LVEF. Similar results were seen in both groups. Minimal lumen diameter in group 1 increased from  $0.7 \pm 0.5$  mm to  $1.4 \pm 0.5$  mm after ELCA and finally to  $3.0 \pm 0.4$  mm. Minimal lumen diameter in group 2 increased from  $0.7 \pm 0.4$  mm to

1.3 ± 0.5 mm after the procedure to a final diameter of 3.0 ± 0.5 mm. A comparable percentage of thrombus burden was ablated by ELCA in both groups. TIMI flow in group 1 improved from 1.4 ± 1.2 to 1.2 to 2.7 ± 0.7 after ELCA and finally to 2.9 ± 0.3. TIMI flow in group 2 improved from 2.0 ± 1.0 to 2.8 ± 0.6 after ELCA and finally to 2.9 ± 0.4. This small study demonstrates that ELCA as an adjunctive therapy may improve PCI success rates for patients with depressed LVEF, but additional well-designed studies are needed to support this conclusion.

Ilkay et al. (2005) conducted a non-randomized experimental study to compare the effects of PTCA and ELCA on ST resolution in patients with acute MI. A stent was inserted after ELCA in 36 patients (group I) and a stent was inserted after balloon angioplasty in 44 patients (group II). In group I, complete ST resolution was observed in 75% of patients, partial resolution in 22%, and resolution did not occur in 3% of patients. In group II, complete, partial and unsuccessful ST resolution rates were 41%, 45%, and 14%, respectively. The mean ST resolution, a good predictor of tissue perfusion, was 82.78 ± 11.89% in group I and 66.36 ± 10% in group II. The authors acknowledged that these findings should be supported by large randomized studies.

Dorr et al. (2006) conducted a randomized controlled trial to assess the feasibility and safety of ELCA in acute MI. A number of secondary endpoints were also evaluated, including final TIMI flow, minimal luminal diameter, and diameter stenosis. Patients who presented within 12 hours of symptom onset were randomly assigned to ELCA plus adjunctive PCI and stent implantation (n=14), or to PCI and stent implantation alone (n=13). There were no significant differences in main procedural results between the two groups. Successful laser device delivery was achieved in all patients, and the core laboratory observed no residual thrombus in any of the cases. Diameter stenosis decreased from 94.3 ± 9.6 to 20.7 ± 10.3% in the ELCA group and from 82.7 ± 16.8 to 18.9 ± 5.5% in the control group (p=ns). TIMI flow increased from 0.7 ± 1.2 to 2.8 ± 0.4 in the ELCA group and from 1.7 ± 1.5 to 3.0 ± 0 in the control group (p=ns). The corrected TIMI frame count (cTFC), a count of the number of angiographic frames elapsed until the contrast material arrives in the distal bed of the vessel, was also similar in both groups, but the cTFC gain was higher in the ELCA group than the control group (53 ± 14% compared to 35 ± 20%, p<0.05). The authors stated that laser angioplasty is feasible and safe, but further randomized trials are needed to assess the benefit of laser angioplasty in acute MI.

### Professional Societies/Organizations

The American College of Cardiology/American Heart Association (ACC/AHA) 2005 Guideline Update for Percutaneous Coronary Intervention does not include ELCA in treatment recommendations. In a discussion of techniques associated with PCI, the authors state that, despite the improvement in acute results seen for rotational atherectomy and excimer laser, there is no evidence that these devices improve late outcomes in lesions that can be safely treated with balloon angioplasty or stenting alone (Smith et al., 2006). ELCA is not mentioned in a 2007 focused update of the 2005 guidelines (King et al., 2008). There have been no updates to the guideline since 2007.

### Summary

Excimer laser coronary angioplasty (ELCA) was introduced prior to the advent of drug-eluting stents, and showed early promise as an alternative method of angioplasty to reduce the long-term complications and high restenosis rates associated with other angioplasty and traditional stenting techniques. Results from clinical trials evaluating ELCA alone or as an adjunctive treatment for coronary artery stenosis and in-stent restenosis, however, did not demonstrate improved outcomes compared to established techniques. ELCA has also been proposed as a treatment for patients with acute MI, and in patients with depressed left ventricular ejection fraction. There is insufficient evidence in the published medical literature, however, to demonstrate the safety and efficacy of ELCA.

---

## Coding/Billing Information

**Note:** This list of codes may not be all-inclusive.

### Experimental/Investigational/Unproven/Not Covered:

CPT* Codes	Description
93799 <sup>†</sup>	Unlisted cardiovascular service or procedure

† **Note: Experimental/ Investigational/ Unproven and Not Covered when used to report excimer laser coronary angioplasty (ELCA).**

ICD-9-CM Diagnosis Codes	Description
	All codes

**\*Current Procedural Terminology (CPT®) © 2010 American Medical Association: Chicago, IL.**

## References

1. Ajani AE, Waksman R, Kim HS, Satler LF, Pichard AD, Kent KM, et al. Excimer laser coronary angioplasty and intracoronary radiation for in-stent restenosis: six-month angiographic and clinical outcomes. *Cardiovasc Radiat Med.* 2001 Jul-Sep;2(3):191-6.
2. Appelman YE, Koolen JJ, Piek JJ, Redekop WK, de Feyter PJ, Strikwerda S, et al. Excimer laser angioplasty versus balloon angioplasty in functional and total coronary occlusions. *Am J Cardiol.* 1996 Oct 1;78(7):757-62.
3. Appelman YE, Piek JJ, Redekop WK, de Feyter PJ, Koolen JJ, David GK, et al. Clinical events following excimer laser angioplasty or balloon angioplasty for complex coronary lesions: subanalysis of a randomised trial. *Heart.* 1998 Jan;79(1):34-8.
4. Appelman YE, Piek JJ, Strikwerda S, Tijssen JG, de Feyter PJ, David GK, et al. Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary artery disease. *Lancet.* 1996 Jan 13;347(8994):79-84.
5. Appelman YE, Piek JJ, van der Wall EE, Redekop WK, van Royen EA, Fioretti PM, et al. Evaluation of the long-term functional outcome assessed by myocardial perfusion scintigraphy following excimer laser angioplasty compared to balloon angioplasty in longer coronary lesions. *Int J Card Imaging.* 2000 Aug;16(4):267-77.
6. Batyraliev TA, Pershukov IV, Niyazova-Karben ZA, Karaus A, Calenici O, Guler N, et al. Current role of laser angioplasty of restenotic coronary stents. *Angiology.* 2006 Jan-Feb;57(1):21-32.
7. Dahm JB, Ebersole D, Das T, Madyhoon H, Vora K, Baker J, et al. Prevention of distal embolization and no-reflow in patients with acute myocardial infarction and total occlusion in the infarct-related vessel: a subgroup analysis of the cohort of acute revascularization in myocardial infarction with excimer laser-CARMEL multicenter study. *Catheter Cardiovasc Interv.* 2005 Jan;64(1):67-74.
8. Dorr M, Vogelgesang D, Hummel A, Staudt A, Robinson DM, Felix SB, Dahm JB. Excimer laser thrombus elimination for prevention of distal embolization and no-reflow in patients with acute ST elevation myocardial infarction: results from the randomized Laser AMI study. *Int J Cardiol.* 2007 Mar 2;116(1):20-6. Epub 2006 Aug 7.
9. ECRI Institute. Laser Angioplasty for Coronary Artery Disease. Plymouth Meeting (PA): ECRI Institute Health Technology Assessment Information Service; 2001 Sept. 67 p. (Evidence Report; no. 56). Available at URL address: <http://www.ecri.org>
10. ECRI Institute. Hotline Response [database online]. Plymouth Meeting (PA): ECRI Institute; Oct 3 2005. Laser Angioplasty for Coronary Artery Disease. Available at URL address: <http://www.ecri.org>
11. Grech ED. ABC of interventional cardiology: percutaneous coronary intervention—I: history and development. *BMJ.* 2003 May 17;326(7398):1080-2.

12. Ilkay E, Karaca I, Akbulut M, Kilicoglu AE, Yavuzkir M, Arslan N. Excimer laser coronary angioplasty in acute myocardial infarction. *Asian Cardiovasc Thorac Ann.* 2004 Dec;12(4):291-5.
13. Ilkay E, Karaca I, Yavuzkir M, Akbulut M, Pekdemir M. The effect of interventional treatment in acute myocardial infarction on ST resolution: a comparison of coronary angioplasty with excimer laser angioplasty. *Angiology.* 2005 Jul-Aug;56(4):377-84.
14. Karaca I, Ilkay E, Akbulut M, Yavuzkir M. Treatment of in-stent restenosis with excimer laser coronary angioplasty. *Jpn Heart J.* 2003 Mar;44(2):179-86.
15. King SB, Smith SC, Hirshfeld JW, Jacobs, Morrison DA, Williams DO. 2007 focused update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: (2007 Writing Group to Review New Evidence and Update the 2005 ACC/AHA/SCAI Guideline Update for Percutaneous Coronary Intervention). *J Am Coll Cardiol* 2008 Jan 15;172-209.
16. Köster R, Hamm CW, Seabra-Gomes R, Herrmann G, Sievert H, Macaya C, et al. Laser angioplasty of restenosed coronary stents: results of a multicenter surveillance trial. The Laser Angioplasty of Restenosed Stents (LARS) Investigators. *J Am Coll Cardiol.* 1999 Jul;34(1):25-32.
17. Köster R, Kahler J, Terres W, Reimers J, Baldus S, Hartig D, et al. Six-month clinical and angiographic outcome after successful excimer laser angioplasty for in-stent restenosis. *J Am Coll Cardiol.* 2000 Jul;36(1):69-74.
18. Mehran R, Dangas G, Mintz GS, Waksman R, Abizaid A, Satler LF, et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: comparative mechanisms and results. *Circulation.* 2000 May 30;101(21):2484-9.
19. Mehran R, Mintz GS, Satler LF, Pichard AD, Kent KM, Bucher TA. Treatment of in-stent restenosis with excimer laser coronary angioplasty: mechanisms and results compared with PTCA alone. *Circulation.* 1997 Oct 7;96(7):2183-9.
20. Rebuzzi AG, Niccoli G, Ferrante G. Acute myocardial infarction interventional procedures: primary percutaneous coronary intervention versus facilitated percutaneous coronary intervention, rescue angioplasty, rescue excimer laser. *Minerva Cardioangiol.* 2007 Feb;55(1):73-82.
21. Reifart N, Vandormael M, Krajcar M, Gohring S, Preusler W, Schwarz F. Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study. *Circulation.* 1997 Jul 1;96(1):91-8.
22. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). *J Am Coll Cardiol.* 2006 Jan 3;47(1):e1-121.
23. Strikwerda S, Montauban van Swijndregt E, Foley DP, Boersma E, Umans VA, et al. Immediate and late outcome of excimer laser and balloon coronary angioplasty: a quantitative angiographic comparison based on matched lesions. *J Am Coll Cardiol.* 1995 Oct;26(4):939-46.
24. Topaz O, Ebersole D, Dahm JB, Alderman EL, Vora MK, Baker JD, Das T. CARMEL Excimer Laser Interventional Study Group. Excimer laser in myocardial infarction: a comparison between STEMI patients with established Q-wave versus patients with non-STEMI (non-Q). *Lasers Med Sci.* 2008 Jan;23(1):1-10. Epub 2007 Apr 11.

25. Topaz O, Ebersole D, Das T, Alderman EL, Madyoon H, Vora K, et al. Excimer laser angioplasty in acute myocardial infarction (the CARMEL multicenter trial). Am J Cardiol. 2004 Mar 15;93(6):694-701.
26. Topaz O, Minisi AJ, Bernardo N, Alimar R, Ereso A, Shah R. Comparison of effectiveness of excimer laser angioplasty in patients with acute coronary syndromes in those with versus those without normal left ventricular function. Am J Cardiol. 2003 Apr.
27. United States Food and Drug Administration (FDA); Center for Devices and Radiological Health. Spectranetics CVX-300 Excimer Laser Coronary Angioplasty System. Accessed April 6, 2010. Available at URL address:  
<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pmasimplesearch.cfm?db=pma&id=16323>

## Policy History

<u>Pre-Merger Organizations</u>	<u>Last Review Date</u>	<u>Policy Number</u>	<u>Title</u>
CIGNA HealthCare	05/15/2008	0342	Excimer Laser Coronary Angioplasty

"CIGNA", "CIGNA HealthCare" and the "Tree of Life" logo are registered service marks of CIGNA Intellectual Property, Inc., licensed for use by CIGNA Corporation and its operating subsidiaries. All products and services are provided by such operating subsidiaries and not by CIGNA Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, CIGNA Health and Life Insurance Company, CIGNA Behavioral Health, Inc., CIGNA Health Management, Inc., and HMO or service company subsidiaries of CIGNA Health Corporation and CIGNA Dental Health, Inc. In Arizona, HMO plans are offered by CIGNA HealthCare of Arizona, Inc. In California, HMO plans are offered by CIGNA HealthCare of California, Inc. In Connecticut, HMO plans are offered by CIGNA HealthCare of Connecticut, Inc. In North Carolina, HMO plans are offered by CIGNA HealthCare of North Carolina, Inc. In Virginia, HMO plans are offered by CIGNA HealthCare Mid-Atlantic, Inc. All other medical plans in these states are insured or administered by Connecticut General Life Insurance Company or CIGNA Health and Life Insurance Company.